US/UK/Canada

Share

Links

Pick a time period -
Tags ( Active)

BICO Publishes Interim Report January – March 2022: Continued growth in sales, improved profitability and focus on commercial synergies

A continued display of strong demand for products and services resulting in organic growth above target, complemented by EBITDA levels paving the way for reaching profitability in 2022BICO is the future of life-saving treatments. We are reducing the organ shortage and speeding up drug development by providing accessible life science solutions that combine biology and technology. January – March 2022 · Net sales amounted to MSEK 477.2 (129.5), which corresponded to an increase of 268% (241) compared to the corresponding period previous year. Organic growth amounted to 52% (62). ·

BICO Group adds senior IR manager to its executive management

Åsa Hillsten has been appointed SVP and Head of IR at BICO and will be a member of the company’s executive management This newly created position constitutes a step in BICO’s continued efforts to increase the service level to the market, improve the clarity of its communication and clarify its business model for the investor market.Åsa Hillsten has more than fifteen years of solid experience in international strategic communication and IR issues at the executive management level at growth companies in several sectors. Former positions include Head of IR and communication roles at Catena

Invitation to presentation of BICO’s Q1 results 2022

BICO’s interim report for the first quarter that ended on March 31, 2022 will be published in English and in Swedish on Wednesday May 18 2022 at 07:00 CEST. Following the release of the report, combined presentation audiocasts and telephone conferences with the opportunity to ask questions will be held in English at 09:00 CEST and 16:00 CEST on the same day, with CEO Erik Gatenholm, CTO Hector Martinez, Interim CFO Mikael Engblom presenting the report. The presentation audiocasts will be accessible via the following links: Morning audiocast, at 09:00 CEST: https://tv.

BICO acquires Allegro 3D, adding new light-based 3D bioprinting technology – complementing the existing offering of application tailored products

Adding Allegro 3D to the portfolio enables BICO Bioprinting to strengthen its position as the global leader in providing 3D bioprinters. BICO has a robust portfolio of bioprinters, utilizing extrusion based, 2PP and DLP technologies.BICO has acquired all the shares in San Diego-based Allegro 3D Inc. (“Allegro 3D”) for an up-front enterprise value of USD 6 million. Additionally, the shareholders can receive USD 5 million in an earnout payment contingent on Allegro 3D's financial performance in the coming two years. The entire purchase price will be paid in cash. Allegro 3D’s patented light-

Business update for BICO Group AB (publ)

BICO hereby provides an extraordinary update on the company's financial and operational development. The information precedes the interim report for the period January-March 2022, which will be published on May 18, 2022.The business update provides a preliminary announcement of the company's financial performance as of March 31, 2022, and indicates that BICO delivered results that are in line with and exceed the company's financial targets. The financial targets, which have previously been communicated, state that the annual organic growth should be above 35 percent, and that the company

New Interim CFO at BICO

Mikael Engblom will take the position as interim CFO for BICO (publ) from 29 April 2022 until a new permanent CFO is in place. Engblom will be part of Group management during this period.BICO announced on April 26, 2022 that the former CFO has left the company and that a recruitment process for a new CFO has begun. While the process is ongoing, Mikael Engblom will assume the role of interim CFO at BICO. Engblom most recently came from the role of CFO at Vitrolife. Prior to that, he worked as a controller at Vitrolife and Volvo Cars. He has a master's degree in business administration from

BICO's Board of Directors: "Full confidence in the CEO, management and current strategic direction"

With regards to ongoing communication in the media and Gusten Danielsson’s statement in Dagens Industri prompted by the fact that he recently chose to resign from his position, the Board of Directors has chosen to address the issue. Both the Board of Directors and management have intended to handle the situation professionally. There has been speculation in the media about the incident and the former employee has also quickly expressed opinions about the CEO and the leadership of the company. The Board of Directors would like to point out that the company has been careful to follow both

Bulletin from Annual General Meeting in BICO Group AB (publ)

The following resolutions were passed at the Annual General Meeting (the “AGM”) of BICO Group AB (publ) (“BICO” or the “Company”) held today on 26 April 2022 in Gothenburg, Sweden. Adoption of Income Statement and Balance Sheet for the Financial Year 2021 and Discharge from Liability The AGM resolved to adopt the income statement and the consolidated income statement for the financial year 2021 as well as the balance sheet and the consolidated balance sheet as of 31 December 2021, as set out in the annual report. The members of the Board of Directors and the managing director were

BICO's CFO Gusten Danielsson leaves his assignment

With immediate effect, BICO's CFO, Gusten Danielsson leaves the company and his role as CFO. A recruitment process for a new CFO has begun and for the time being, the VP of Finance, Tommy Niklasson will take responsibility for BICO's finance department. “I would like to thank Gusten Danielsson for his great contribution and commitment from BICO's start in 2016 until today. The recruitment process that has been initiated, aims to find a new CFO with solid experience of leading and organizing a finance department in listed, international groups with a simultaneous focus and drive on

The BICO Group has been awarded 7 iF design awards for excellence in product design

Handed to products that excel in their design and vision, the iF awards are voted on by a jury of 132 leading designers from across the globe with the goal to identify products which demonstrate the adoption of modern design trends and outstanding craftsmanship.  For the third year in a row, BICO has taken home the award and extends its haul to 11 iF design awards in total, officially ranking within the top 10 companies in the healthcare/medical field. Each business area was represented in the 7 awards that were handed out this year.  BICO Biosciences was awarded an impressive 4 awards

BICO Companies win Red Dot Design Award for Outstanding Product Design

Two companies in BICO's Biosciences business area have taken home Red Dot accolades for their groundbreaking product design.Today, Discover Echo and CYTENA BPS, two companies’ part of the BICO Biosciences business areas were recipients of the illustrious Red Dot Design awards. CYTENA BPS’ S.NEST™ was further recognized as part of the “Best of the Best”, the highest accolade available.   “This marks BICO’s third year in a row being recognized by the Red Dot committee, a wonderful testament to the passion and persistence shown across the organization to develop user centric designed

MatTek Announces Production and Shipping of EpiOral Tissues from European Facility to Better Service the Wider Market

MatTek Life Sciences will produce and distribute EpiOral from its production facility in Slovakia, continuing the BICO groups’ focus on providing on-demand tissues to the European market.MatTek Life Sciences, a Boston-area tissue engineering company and a part of the BICO Group, announced today its European facility in Bratislava, Slovakia, will begin producing and shipping EpiOral, a lab-grown human oral epithelial tissue used to evaluate consumer product safety and efficacy. This expansion in production enables shorter shipment times to the European market, while maintaining the highest

Notice to Attend the Annual General Meeting in BICO Group AB (Publ)

The shareholders in BICO Group AB (publ), reg. no. 559050-5052 (the “Company” or “BICO”), with its registered office in Gothenburg, are hereby invited to the annual general meeting on Tuesday 26 April 2022 at 17:00 PM, at Konferensrum 5th floor, Biotech Center, Arvid Wallgrens backe 20, SE-413 46 Gothenburg.NOTIFICATION, ADVANCE VOTING, ETC. Notification Shareholders who wish to participate at the annual general meeting shall: · firstly, be entered in the share register maintained by Euroclear Sweden AB no later than on Thursday 14 April 2022 (for nominee-registered shares, also

MatTek Enters Distribution Agreement and Strategic Partnership with Cell4Pharma

MatTek Life Sciences will distribute Cell4Pharma’s ciPTEC renal cells and utilize the technology in the development of a new in vitro kidney model.MatTek Life Sciences, a Boston-area tissue engineering company and a member of the BICO Group, announced today it has entered into a distribution agreement and strategic partnership with Cell4Pharma, a Netherlands-based company specializing in commercially available human renal cells, to distribute its products in the US as well as develop a new in vitro kidney model. MatTek will act as a US-based distributor for Cell4Pharma’s ciPTEC renal

BICO publishes Annual Report 2021

BICO has published Annual Report 2021 for the financial year which covers January 1 to December 31, 2021. The Annual Report is available on BICO’s website: www.bico.com/investors. The printed version of the Annual Report 2021 will be available from the beginning of April. For further information, please contact:Gusten Danielsson, EVP and CFOPhone (US): +1 (857) 332 2138Phone (Sweden): +46 70 991 86 04     Email: gd@bico.com This is information that BICO is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication on March 16,

Nanoscribe introduces Extra Large Feature Print Set to extend 3D Microfabrication capabilities to print centimetre-sized structures

3D printing based on Two-Photon Polymerization closes gap with high-resolution DLP and projection micro stereolithography (PµSL)Nanoscribe, a BICO company, introduces the Extra Large Features (XLF) Print Set, to expand the manufacturing range for its high-precision 3D printer Quantum X shape from nano- and microscale structures to millimeter- and centimeter-sized objects, while maintaining particularly complex structures and filigree details as is the case in many biomedical and microfluidic applications. But above all, the new XLF Print Set speeds up high-precision 3D printing many times

Cellenion Announces Opening of BICO’s First Single Cell Analysis Centre of Excellence

Cellenion will provide a range of comprehensive single cell analyses and handling services from its new state-of-the-art laboratories in Lyon.Cellenion , a  BICO  company, announced today the opening of the BICO group’s first Single Cell Analysis Centre of Excellence at its facilities in Lyon. This state-of-the-art centre will offer a range of services (cellenSERVICES) to companies and academic groups seeking complete solutions for their single cell projects from tissue dissociation to single cell isolation, library preparation, sequencing and

SCIENION Announces Study Results for PoC-BoSens, an Optofluidic-based Infectious Disease Diagnostic Platform

The study demonstrated the success of an optofluidic-based Point-of-Care (PoC) diagnostic system for the analysis of protein-protein interactions.Today SCIENION, a BICO company and leading developer of miniaturized multiplex diagnostic tests, announced the completion of the diagnostic research project PoC-BoSens led by the Fraunhofer Institute for Reliability and Microintegration (IZM). The PoC-BoSens platform is a revolutionary label-free Point-of-Care device based on three-dimensional photonic bottle resonators (3D-BMRs) for real-time high-sensitive measurement of disease-relevant

CELLINK Launches the BIO CELLX, a First of its Kind Biodispensing Platform to Automate 3D Cell Culture

The BIO CELLX provides cell biologist with pre-validated protocols to eliminate barriers for automating 3D cell-based assays targeting cancer research and drug discovery.Today CELLINK, A BICO Company, launched the BIO CELLX a novel system that automates 3D cell culture workflows by leveraging pre validated protocols. The BIO CELLX builds upon CELLINK’s impressive bioprinting portfolio utilizing proven technologies like the patented Clean Chamber combined with a unique new method for effortless mixing of hydrogels and cells, high precision dispensing and automatic nozzle priming to create a

BICO Group AB (publ) announces an increase in number of shares and votes

The number of shares and votes in BICO Group AB (publ) (“BICO”) have increased following the exercise of 756,000 warrants pursuant to BICO’s warrant programme 2018 for subscription of 756,000 shares of series B. As of February 28, 2022, the total number of registered and outstanding shares of BICO amounts to 64,086,269 of which 1,500,000 are shares of series A, corresponding to a total of 15,000,000 votes and 62,586,269 are shares of series B, corresponding to a total of 62,586,269 votes. Consequently, the total number of votes for the two classes of shares amounts to 77,586,269. The

BICO has reached a beneficial and sustainable solution with Organovo

We are glad to announce that we have reached a settlement with Organovo in which we agreed to resolve all aspects of the disputes between the parties. Organovo and BICO were engaged in several legal disputes regarding Organovo’s patents. Under the new agreement, all civil actions regarding potential infringements and IPRs concerning validity of Organovo’s patents are dismissed and/or terminated. Both BICO and Organovo have released each other from all previous claims, demands, liabilities and costs in favor of finding a beneficial and sustainable solution created through this patent license

Year-end report 2021: Strong growth, positive EBITDA, and a clear plan for increased profitability

Fourth quarter: October-December 2021 · Net sales amounted to MSEK 519.1 (207.0), which corresponds to an increase of 151% (391) compared to the corresponding period previous year. Organic growth amounted to 25% (88). Adjusted for sales of non-recurring pandemic-related hygiene products the previous year, the quarter’s organic growth was 30%. · Adjusted EBITDA* amounted to MSEK 24.1 (45.9), which corresponded to a margin of 4.6% (22.2). · EBITDA amounted to MSEK 13.0 (43.6), corresponding to a margin of 2.5% (21.1). · Net profit/loss for the period amounted to MSEK -25.9 (20.4)

Biosero Expands Laboratory Automation Capabilities with New Product Launches

New products in the Green Button Go® portfolio offer customers more flexibility, greater control, and streamlined performance for automated workflows.Biosero, Inc., a BICO company, and a developer of laboratory automation solutions to orchestrate scientific discoveries, today announced the launch of several new products and features in the company’s Green Button Go® software suite. Together, these products deliver an array of advanced capabilities to help customers streamline, control, and generate better results from their automated lab systems. Biosero’s Green Button Go software allows

There are no items matching the current filter
There are no more items matching the current filter
Back to top